You are reading the beginning of the May 15th DHC Proposed Draft Guidance for FDA Consideration document itself. If you’re looking for the DHC press release on the same subject, click here. If you wish to reach out to us …

In early April, Endpoints News published “Avoiding Cell Therapy Manufacturing Gridlocks — a Do’s and Don’ts Guide,” in which guidance by our CEO, Anthony Davies, figured prominently. (One of his many quotes is above in the header on this page.)…

5 New Year’s Resolutions For Advancing The CGT Manufacturing Paradigm

By Anna Rose Welch, Director, Cell & Gene Collaborative

As I began plotting this article series following my conversation with Katy Spink, COO and Managing Partner of Dark Horse Consulting, …

From the Canadian Journal of Chemical Engineering via the Wiley Online Library comes an article authored by Dark Horse Senior Consultant Sara Mills in tandem with Elizabeth Csaszar and Peter Zandstra. 

Access the full article, “Process evolution in cell and …

Principal Nate Manley was interviewed by Insights Bio this month for a Cell and Gene Therapy Insights raw and starting materials spotlight article entitled, “Emerging trends in control and regulation of immunotherapy cellular starting materials.”

Read the full article, including …

published 16 Mar 2021 at written by Amanda Micklusreproduced with permission

PDF available for download, here

Regenerative medicines have made significant advancements in …

CEO Anthony Davies had the distinct honor of being on the panel for the inaugural episode of Phacilitate: Talks, a socially-distanced podcast for the Cell & Gene Therapy space. 

…

As founder of cell and gene therapy (CGT) specialist firm Dark Horse Consulting Group in California, Anthony Davies speaks from a quarter …

By Nathan Manley & Katy Spink

The cell therapy field is currently in an exciting era of expansion, with a large number of candidate therapies advancing into clinical testing and many more progressing through preclinical pipelines. As the number of …

by Gareth Macdonald

The cell therapy sector faces a cost of goods sold (COGS) crisis and needs to get beyond the “product is the process” mind-set says Anthony Davies, CEO of Dark Horse Consulting.

Cell and gene therapies have attracted …

by Dan Stanton

Fully closed and automated platforms are key to reducing the current high costs of cell and gene therapy manufacturing, say industry experts.

Cell and gene therapies (CGTs) have come a long way over the past two years, …